^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An open-label, dose-escalation, and extension study of Camrelizumab combined with pyrotinib maleate and CapeOX in first-line treatment of HER2-positive gastric cancer
Excerpt:
...Histological or cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma3. ...
Trial ID:
Source:
Title:
Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
Published date:
11/20/2023
Excerpt:
Pyrotinib plus camrelizumab and chemotherapy showed promising efficacy in the first-line treatment of advanced HER2-positive G/GEJ cancer. The safety profile was consistent with known toxicities of the agents, and no new or unexpected safety signals were identified.
Secondary therapy:
Chemotherapy
DOI:
10.1016/j.eclinm.2023.102314
Source:
Title:
First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study.
Published date:
01/17/2023
Excerpt:
The objective response rate and disease control rate were 96.0% and 100%, respectively. The 12-month progression-free survival rate and overall survival rate were 77.1% and 89.3%, respectively….Camrelizumab plus pyrotinib and chemotherapy showed promising efficacy in the first-line treatment of HER2-positive G/GEJ cancer, with acceptable safety profiles.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2023.41.3_suppl.356
